BioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death
Research suggests molecular iodine specifically targets certain types of breast cancer cells, suggests strong anti-proliferative effects
Mar 30, 2017
MENLO PARK, Calif., March. 30, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, will share early preclinical research that suggests potent anti-proliferative and apoptotic effects of molecular iodine on two types of breast cancer cell lines.
Findings will be shared via a poster entitled "Elucidating the Mechanism of Action of Molecular Iodine on Breast Cancer Cells," which will be presented at the American Association for Cancer Research Annual Meeting, from 1 p.m. to 5 p.m. Monday, in Washington.
BioPharmX researchers analyzed the impact of molecular iodine on gene expression and antiproliferative changes in the luminal A breast cancer derived cell line (MCF-7), the triple negative breast cancer cell line (MDA-MB231) and primary human mammary epithelial cells from a healthy donor. They found expressions of nuclear hormone receptors PPARs and RXR were up-regulated and BCL-2 and Caspase 3, both regulators of cell death, were increased. This suggests that molecular iodine can specifically inhibit cellullar proliferation and drive cell death in certain breast cancer cell lines without apparent toxicity to normal breast cells.
"The possibility that a known, non-toxic, and non-chemotherapeutic molecule may have a differential regulating effect on breast cancer cells versus normal breast cells is very exciting," said Lee P. Shulman, Professor of Ob/Gyn at the Feinberg School of Medicine of Northwestern University in Chicago, Illinois. "The results indicate that iodine inhibits the in vitro proliferation of MCF-7 and MDA-MB231 breast cancer cells."
The researchers' gene expression analysis using qRT-PCR also confirmed that key cell cycle genes responsible for controlling G1-S phase transition were significantly up-regulated.
The findings of our in vitro research studies demonstrate that molecular iodine exhibits antiproliferative and apoptotic effects in mammary cancer cell lines and further elucidates molecular iodine's cellular mechanism of action in these breast cancer cells.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding potential outcomes of its research programs, whether molecular iodine can successfully targets certain types of breast cancer cells, and whether molecular iodine will have anti-proliferative effects. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
SOURCE BioPharmX Corporation
For further information: For further information: Nina Brauer; Senior Manager, Marketing & Communications; firstname.lastname@example.org; (650) 889-5030; OR Media Contact; Jim Martinez; RightStoryGroup LLC; email@example.com; (312) 543-9026